Related Articles
A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer
Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
Real‑world effect of bevacizumab and eribulin on metastatic breast cancer using a propensity score matching analysis
Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer